Nasal Spray STIMATE Returning To Market This Fall

Ferring Pharmaceuticals has announced their nasal spray STIMATE will return to the market this fall following a six year absence.

The nasal spray for Hemophilia A and von Willebrand Type 1 patients was voluntarily recalled in 2020 due to what the pharmaceutical company called a “packaging-related issue, which has now been resolved.”

Ferring announced in a letter to the community the FDA had approved STIMATE’s return to the market in early July 2026, and that the product will become available to patients in October.

The full letter is available here.